Memory for antigens once encountered is a hallmark of the immune system of vertebrates, providing us with an immunity adapted to pathogens of our environment. 
| MEMORY PL A S MA CELL S
From a personal point of view, we became interested in the lifestyle of memory lymphocytes when we started to analyze the persistence of plasma cells in the bone marrow.
1,2 Plasma cells had been identified as antibody-secreting cells in 1947. 3 It had been noted early on that they disappear from secondary lymphoid organs when immune reactions are finished, 3, 4 an observation leading Astrid Fagraeus to state that the plasma cell is "a cell which has already passed its greatest functional activity". 3 A second observation apparently supported this view, in that plasma cells isolated from secondary lymphoid organs died rapidly in cell culture, unlike other lymphocytes. [5] [6] [7] [8] The apparently short lifespan of plasma cells created a conceptual problem, namely how to explain the persistence of specific antibody titers in the blood, long after termination of an immune response. 9 One solution to this problem would be if immune reactions would not terminate, but continue to smolder, driven by residual antigen, at very low to undetectable concentrations. 10 Plasma cells would have a defined short half-life and dying plasma cells would be replaced constantly and over time, by newly generated ones. In other words, persistent humoral antibody titers would not reflect "memory" but rather a chronic immune reaction. In a modification of this concept, Lanzavecchia and colleagues later postulated that bystander activation of memory B lymphocytes could generate plasmablasts replenishing the ranks of dying plasma cells. 11 In summary, the prevailing concepts say that plasma cells have a defined, short half-life, and that in order to maintain persistent antibody titers, ie, "humoral memory", their numbers would have to be replenished constantly, either by cognate or bystander activation of B lymphocytes, their precursors. 12 An alternative concept had been suggested in 1974 by Benner and colleagues, who had observed that, while plasma cells disappeared from secondary lymphoid organs when an immune reaction to a defined antigen terminated, plasma cells specific for that antigen could easily be detected in the bone marrow at later time points. 13 Twenty years later we showed that plasma cells generated DOI: 10.1111/imr.12656
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in a defined murine immune reaction were thereafter maintained in the bone marrow for up to 120 days, as cells resting in terms of proliferation, in constant numbers, reflecting about 10%-20% of the originally generated plasma cell population. 1, 2, 14 At about the same time, Slifka and colleagues, using an entirely different technical approach, showed that plasma cells of a given immune reaction would persist in murine bone marrow, even if their regeneration from activated B lymphocytes was blocked. 15 Similarly, treatment of human patients with Rituximab did not ablate humoral memory. Rituximab is an antibody depleting circulating B lymphocytes which express CD20, but not plasma cells which do not express CD20. Titers of serum antibodies to measles or tetanus remained constant. 16 Also in mice, depletion of CD20-expressing B lymphocytes affected neither the numbers of bone marrow plasma cells nor the persistence of antibody titers. 17 Recently, assessment of lifetimes of individual plasma cells in the bone marrow of macaques has confirmed that those plasma cells can persist there for a decade. 18 Similarly, they can survive for decades in the human gut, 19 and it has been discussed that long-lived mucosal plasma cells may play a role in maintaining the mucosal microbiota. 20 Apparently, plasma cells can also persist in inflamed tissue, as in the inflamed kidneys of NZB/W mice 21, 22 or the inflamed central nervous system of mice with experimental autoimmune encephalomyelitis. 23 During acute inflammation in the inflamed tissue, the persistence of plasma cells, in particular those secreting antibodies specific for pathogens driving the inflammation, would provide local protection. In chronically inflamed tissues longlived plasma cells secreting autoantibodies might themselves drive the inflammation. Pathogenic long-lived plasma cells are a novel therapeutic target.
24,25
The persistence of long-lived plasma cells over long time periods qualifies them as true "memory" cells, memorizing the original antigenic challenge independent of continued antigenic stimulation, 1 ie, maintaining information in the absence of the original instruction.
We therefore suggest to designate them "memory plasma cells", replacing the operational term "long-lived" plasma cells used so far in the literature. Whether or not the precursors of these memory plasma cells need an intrinsic "competence", other than the capacity to find the path towards a memory niche, remains to be shown. So far, it appears that most if not all memory plasma cells are derived from memory B lymphocytes, either in extended primary or in secondary immune responses, and that their generation is dependent on help from T lymphocytes (reviewed in Ref. 26 ).
Memory plasma cells are diverse regarding expression of different classes of antibodies, different chemokine receptors and other surface receptors. 27 While their precursors express CD38 at rather low levels, memory plasma cells express high levels of CD38. 28, 29 This CD38 is apparently distinct from CD38 on other cells; it is selectively recognized by a plasma cell-specific antigen receptor of lamprey, because it is dimerized and shows NAD glycohydrolase activity. 30 Within CD38 high plasma cells of the bone marrow, further diversity has been described regarding expression of other surface molecules. 28 Among those CD19 has raised some interest recently as a candidate marker for memory plasma cells maintaining long-term memories, 31, 32 similar to memory CD4 + T lymphocytes of the bone marrow, as will be discussed later. 33 Apparently loss of CD19 expression can occur already at the transition from plasmablast to plasma cell 34 . Whether or not CD19 qualifies as a target for the selective ablation of memory plasma cells secreting pathogenic antibodies remains to be shown. 35 
| CONDITIONAL SURVIVAL OF MEMORY PL A S MA CELL S-THE MEMORY NICHE
Analyzing the lifestyle of memory plasma cells in more detail immediately challenged a second traditional viewpoint, namely the concept of an intrinsic "half-life" of memory lymphocytes. Isolated plasma cells of murine bone marrow survive only for a day or 2 in culture medium, unless this medium is supplemented with cytokines and stimuli for adhesion receptors, like CD44. 7 In vivo, these plasma cells can essentially survive for a lifetime, as discussed above.
Clearly, bone marrow plasma cells have no intrinsic "half-life", but rather survive depending on signals from their environment, most likely cytokines and ligands for adhesion receptors.
The "survival code" of memory plasma cells is still poorly un-
derstood. An essential signal is activation of the B-cell maturation antigen (BCMA/CD269) by one of its ligands, B-cell activating factor (BAFF/BLyS/CD257), or a proliferation inducing ligand (APRIL/ CD256). 36 BCMA is encoded by the tumor necrosis factor receptor superfamily member 17 gene (TNFRSF17), and signaling through the NF-κB pathway regulates expression of the myeloid leukemia cell differentiation protein MCL1, which is essential for survival of bone marrow plasma cells. 37 A second essential signal seems to be integrin α4β1 (VLA-4), a dimer of CD49d (α4 integrin) and CD29
(β1 integrin) and receptor for vascular cell adhesion molecule 1 (VCAM-1/CD106) and fibronectin, and the lymphocyte functionassociated antigen 1 (LFA-1), a dimer of integrin αL (CD11a) and integrin β2 (CD18) and receptor for intercellular adhesion molecule 43 and initial evidence has been reported that this pathway indeed may support plasma cell survival. 44 However, the mTOR pathway, one of the targets of PI3K/ AKT signaling, does not seem to be required for the persistence of memory plasma cells. 45 The dialogue between mesenchymal stromal cells and memory plasma cells of the bone marrow is probably much more sophisti- row. 41 The CXCR4 antagonist AMD3100 blocks the immigration of plasmablasts into and the establishment of memory plasma cells in the bone marrow, strongly suggesting that the plasma cells had been attracted to the stromal cells by CXCL12 47 . In humans (re)vaccinated against tetanus, a wave of newly generated plasmablasts is detectable between days 6 and 8 after vaccination in the blood. In transwell migration assays, these plasmablasts migrate toward CXCL12
gradients. 46 Outside of this time window, only few plasmablasts and plasma cells are detectable in blood, and most if not all of them are obviously derived from mucosal immune responses. 48 In mice, as early as 2 weeks after their generation, plasma cells have lost their mobility, they do not move within the bone marrow, 42 and when isolated from the bone marrow, they do not migrate toward gradients of CXCL12 in transwell migration assays. 14 This is even more surprising, since they still express CXCR4, and react to CXCL12
by improved survival in tissue culture. 7 The immobility of memory plasma cells implies that once their survival niche disintegrates, memory plasma cells will die, because they are not able to move to alternative niches. In regenerating tissue of acute inflammation, this may help to get rid of tissue-resident plasma cells of the acute immune reaction, ie, terminate the peak response. It also may contribute to the age-dependent decay of humoral memory. 49, 50 Although stromal cells are a key element of the memory plasma cell niche, they are not the only element. The classification of antigen-experienced vs circulating memory T cells is still on shaky ground. For human T cells, the classification is according to expression of CD45 isoforms, with memory T cells expressing CD45RO rather than CD45RA. 67, 68 In mice, memory T cells have been classified according to low expression of CD45RB, 69, 70 and stable acquisition of high CD44 expression. 71 Taking a closer look at the functional potential of circulating antigen-experienced T lymphocytes, Sallusto and Lanzavecchia classified them as "central" memory cells, expressing the chemokine receptor CCR7, and "effector" memory cells not expressing CCR7. 72 CCR7 is involved in the organization of immune reactions in secondary lymphoid organs. 73 Thus, central memory T cells would provide a memory for secondary immune reactions, while effector memory T cells would provide immunity directly. In the meantime, the zoo of circulating memory T-cell types, classified according to phenotype and (presumptive) function, has expanded. 74 It includes CD45RA memory stem cells 75, 76 and CD45RA "terminally differentiated" effector memory T cells. 77, 78 This zoo may even expand further in the future, considering that among naive T lymphocytes, those expressing CD31 are truly naive, ie, recent thymic emigrants, while those not expressing CD31 have lost their T-cell receptor recombination excision circles. 79, 80 This indicates that they had been activated to proliferate in the periphery. It remains to be shown whether this activation was triggered by (auto)antigen or not.
In terms of global gene expression, memory T lymphocytes of blood are resting, 81 compartmentalization of antigen-experienced T cells has become a favorite exercise of immunologists. [83] [84] [85] We have shown that GATA3 mediates the epigenetic imprinting of the interleukin-4 (Il4) gene, 86, 87 and how imprinting of the interferon-γ (Ifng) gene is induced by STAT4. 88, 89 Most importantly, we and others have shown that imprinting of cytokine genes in activated naive T cells but not in memory T cells requires progression through the S phase of the first cell division. This is suggesting that imprinting is indeed linked to epigenetic modification of DNA and would explain why cytokine gene expression is faster in secondary than in primary immune reactions. 90 Essentially everything that we think we know about memory T lymphocytes has been analyzed on T cells obtained from murine secondary lymphoid organs, mostly spleen, or human blood. 
| THE LIFE S T YLE OF CIRCUL ATING MEMORY T LYMPHO C Y TE S
of the antigen-experienced T cells of the spleen are rapidly proliferating, while the other 50% are not proliferating at all. Even
| THE BONE MARROW-H UB FOR CIRCUL ATING OR HOME OF RE S IDENT MEMORY T CELL S?
Another indication for homeostatic proliferation of splenic memory T cells had come from analyses of the uptake of bromodeoxyur- Determining proliferation by other methods, bone marrow memory T cells are resting in terms of proliferation. According to staining of Ki-67, more than 90% of murine bone marrow memory CD8 + T cells are in G0 of the cell cycle, more than 180 days after the onset of an intentional immune response, and less than 0.5% are in the S/G2/M phases of cell cycle. 117 The same is true for human memory CD8 + and CD4 + T cells of bone marrow. 33 And finally, ablation of proliferating memory T cells in mice, using cyclophosphamide,
shows that within 14 days, memory CD8 + T cells of the bone marrow are not deleted at all, contrary to their splenic counterparts, as discussed above. This is true for memory T cells of an intentional immune response as well as for the entire population of all CD8 + memory T cells of the bone marrow, those generated by natural infections over time in these mice. 114 It should be noted that this is true also in the presence of Fingolimod (FTY720), blocking sphingosine-1-phosphate-mediated trafficking of lymphocytes, and emptying the murine blood of lymphocytes. These experiments identify most if not all CD8 + memory T cells of the bone marrow as resident cells, resting in terms of proliferation at least for the time of observation.
Bone marrow is a quiet and privileged place, in that it is not connected to the lymphatic vessel system, and can be accessed and exited only via the blood stream. 125 However, the presence of a minor population of circulating memory T cells cannot be excluded and it is likely that occasionally such cells pass by, as had been the case in the adoptive transfer experiments reported by the group of Rafi Ahmed. 110 Evidence for a resident population in the bone marrow of memory CD4 + T lymphocytes is mainly based on their exclusive repertoire of T-cell receptor specificities. In several intentional murine immune responses, antigen-experienced CD4 + T lymphocytes relocated quantitatively to the bone marrow during the contraction phase, ie, within 60 days after onset of the immune reaction. After 120 days, antigen-experienced CD4 + T lymphocytes were no longer detectable in spleen or lymph nodes, while in bone marrow, a stable population had been established. 59 In contrast, the group 
| THE LIFE S T YLE OF BONE MARROW MEMORY T LYMPHO C Y TE S
The presence of antigen-experienced T lymphocytes, both CD8 + and Taken together, this qualifies them as bona fide regulatory memory T cells. 136 In bone marrow as well, about 10% of the memory CD4 T cells express CD25 high , CD127 low , and FOXP3, 33 arguing that those cells are regulatory memory T cells.
CD69 is expressed in humans by about 30% of the CD4 + and 60% of the CD8 + memory T cells of the bone marrow. 33 In mice, 30%-40% of bone marrow CD8 + memory T cells express CD69, 117 and about 40%-50% of bone marrow CD4 + memory T cells. 137 Expression of CD69 is induced upon activation of T cells 138 and therefore has been conceived as a marker of activation, also for bone marrow memory T cells. 133 One of the genes differentially expressed between CD69 + and CD69 − memory CD4 + T lymphocytes of bone marrow is the gene for the receptor for sphingosine-1-phosphate (S1PR1), which is not expressed by CD69 + memory T cells. 33 CD69 is an antagonist of S1PR1, blocking the S1P-mediated egress of lymphocytes from secondary lymphoid organs into the blood. [140] [141] [142] It is remarkable that in CD69 + memory T cells of bone marrow, S1PR1 expression is blocked on the level of transcription, since it has also been reported that CD69 can directly block surface expression of S1PR1. 143 In any case, 
| RE AC TIVATI ON OF BONE MARROW MEMORY T LYMPHO C Y TE S
| " TISSUE-RE S IDENT " VS BONE MARROW-RE S IDENT MEMORY T LYMPHOC Y TE S
It is interesting to note that in the recent hype about "tissueresident" memory T lymphocytes, bone marrow-resident memory T lymphocytes were largely disregarded, quasi the "Cinderella" of memory lymphocytes. [154] [155] [156] [157] [158] [159] In a restricted sense, the term "tissue-resident" has been used by others for antigen-experienced T lymphocytes, in particular CD8 + lymphocytes, of the skin, gut, lung, and other peripheral tissues, mostly barrier tissues. In absolute numbers, the human skin harbors almost twice as many CD45RO + T cells as the peripheral blood. 160 Human bone marrow contains 3-4 times as many CD45RO + T cells as peripheral blood. 33 In peripheral tissues and in the bone marrow, Hobit. 134, 159 The signature genes of "tissue-resident" memory T cells are also expressed by bone marrow-resident memory T cells. 151 That "tissue-resident" memory T cells are indeed resident, ie, do not circulate, has been suggested by parabiosis experiments. 164 For human "tissue-resident" memory T cells of the skin, it has been argued that CCR7-negative cells are residents of the skin, since they are refractory towards treatment with anti-CD52 (Alamtuzumab), depleting circulating memory T cells, including CCR7-expressing memory T cells of the skin. 165 Aside from this notion, the lifestyle of "tissue-resident" T cells is not so clear. Antigen is needed for the differentiation of T cells into "tissue-resident" T cells. 157, 166 They seem to play a prominent role in controlling persistent, latent infections, 167 but apparently can also be maintained in the absence of antigen. 162 What is less clear is the role of the circulating memory T lymphocytes. Are they providing a "short-term" memory, which could last even for years, but declines over time and eventually disappears? Is this the memory maintained in secondary lymphoid organs themselves, like in the spleen and lymph nodes, and leaving them from time to time to circulate through blood and lymph? 
| MEMORY B LYMPHO C Y TE S OF THE BONE MARROW
| PROTEC TION OF IMMUNOLOG IC AL MEMORIE S BY BONE
The analysis of memory plasma cells of bone marrow has generated a novel understanding of how immunological memory is organized by mesenchymal stromal cells, counting memory cells and defining their populations, by direct individual cell contacts. Persistence of the memory cell is conditional on signals from these niches, and not on intrinsic half-lives. Evidence is accumulating that also memory T lymphocytes are maintained in this way, at least those residing in the bone marrow, probably also those residing in barrier tissues. We are still lacking detailed information on the molecular codes of memory niches and their diversity, a challenge for future research. We also need to obtain an understanding of the lifestyle of circulating memory T lymphocytes and memory B lymphocytes. Beyond that, the role of the bone marrow in the maintenance of experienced innate lymphocytes awaits analysis, a topic beyond the scope of the present review. 
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